▁Anal 10.375
yst 4.77734375
s 2.974609375
▁and 4.25390625
▁medical 7.71484375
▁exper 4.03515625
ts 0.0545654296875
▁eager 11.1796875
ly 1.712890625
▁await 2.248046875
▁the 4.296875
▁up 6.19921875
coming 0.4658203125
▁European 9.8046875
▁Society 9.5078125
▁for 4.90234375
▁Medical 3.24609375
▁On 8.6171875
col 3.54296875
ogy 0.73291015625
' 7.96875
s 2.419921875
▁( 6.7421875
ES 5.76171875
MO 0.73095703125
) 1.1005859375
▁annual 8.859375
▁meeting 8.8984375
, 3.529296875
▁set 8.9765625
▁to 1.697265625
▁take 2.28515625
▁place 0.48291015625
▁later 5.69140625
▁this 0.8583984375
▁month 2.2578125
, 1.3984375
▁where 5.00390625
▁new 6.28125
▁evidence 6.99609375
▁regarding 6.9453125
▁British 8.5625
▁Bi 9.4609375
ote 4.53515625
ch 4.5234375
' 5.59765625
s 1.4677734375
▁highly 7.4140625
▁anticip 1.748046875
ated 0.6630859375
▁anti 10.640625
- 1.150390625
can 7.6328125
cer 0.43115234375
▁treatment 8.2109375
, 2.078125
▁Mar 10.9921875
im 8.96875
ast 8.890625
at 5.328125
, 2.830078125
▁is 7.26953125
▁expected 3.525390625
▁to 0.55810546875
▁be 2.53515625
▁presented 4.859375
. 3.052734375
▁Consider 7.60546875
ed 1.427734375
▁a 2.30078125
▁potential 5.2734375
▁break 4.1953125
through 0.034027099609375
▁in 1.6904296875
▁cancer 3.982421875
▁th 5.32421875
era 0.00388336181640625
pe 0.003078460693359375
ut 0.0005431175231933594
ics 0.04229736328125
, 0.454833984375
▁Mar 2.43359375
im 1.25390625
ast 0.386474609375
at 0.038116455078125
▁has 3.50390625
▁gar 6.4609375
ner 0.00010514259338378906
ed 0.0130462646484375
▁attention 2.904296875
▁for 2.359375
▁its 0.7265625
▁unique 3.50390625
▁mechanism 2.599609375
▁of 0.1448974609375
▁action 0.08843994140625
▁and 2.13671875
▁prom 3.984375
ising 0.0015611648559570312
▁pre 3.294921875
cl 0.9873046875
in 4.4465065002441406e-05
ical 0.003604888916015625
▁results 1.14453125
. 0.72314453125
<0x0A> 1.3955078125
Develop 6.39453125
ed 0.2047119140625
▁by 0.5068359375
▁British 5.796875
▁Bi 0.72314453125
ote 0.0015773773193359375
ch 0.225341796875
, 1.76953125
▁Mar 0.91259765625
im 0.12005615234375
ast 0.06256103515625
at 0.0024280548095703125
▁falls 9.6015625
▁under 0.48828125
▁a 2.068359375
▁class 1.3974609375
▁of 0.0275421142578125
▁dru 1.6083984375
gs 0.0011577606201171875
▁known 0.7607421875
▁as 0.020843505859375
▁matrix 8.015625
▁metal 0.238037109375
lo 0.0012712478637695312
prote 0.0164794921875
in 0.070068359375
ase 0.62939453125
▁in 0.37744140625
hib 0.00011038780212402344
itors 0.0142822265625
, 0.92041015625
▁which 1.0107421875
▁work 3.45703125
▁by 0.54248046875
▁target 2.787109375
ing 0.0025348663330078125
▁specific 2.861328125
▁en 1.3095703125
zym 8.130073547363281e-05
es 0.0260467529296875
▁involved 1.68359375
▁in 0.052215576171875
▁the 0.71337890625
▁pro 3.6171875
gression 0.115966796875
▁and 2.275390625
▁spread 1.3671875
▁of 0.06915283203125
▁cancer 0.42138671875
. 0.80810546875
▁Pre 4.8125
lim 1.7470703125
inary 0.0009870529174804688
▁studies 1.8779296875
▁have 0.69189453125
▁shown 0.64013671875
▁prom 2.52734375
ising 0.0001291036605834961
▁results 0.407470703125
, 1.5615234375
▁suggesting 3.76171875
▁that 0.5439453125
▁Mar 0.64208984375
im 0.002826690673828125
ast 0.01812744140625
at 0.0017185211181640625
▁may 1.09765625
▁be 1.1044921875
▁effective 1.5703125
▁in 0.428466796875
▁comb 3.109375
ating 0.2666015625
▁a 1.5869140625
▁range 1.8564453125
▁of 0.0032444000244140625
▁cancer 1.8896484375
▁types 0.54443359375
. 1.46875
▁However 5.16015625
, 0.005237579345703125
▁further 2.30859375
▁evidence 5.1796875
▁is 0.50439453125
▁required 1.6123046875
▁to 0.47265625
▁validate 3.59375
▁these 0.88330078125
▁early 2.3125
▁find 0.5087890625
ings 1.1920928955078125e-06
▁and 1.91015625
▁evaluate 4.765625
▁its 2.46484375
▁safety 3.466796875
▁and 0.64453125
▁effic 0.385009765625
acy 1.8835067749023438e-05
▁in 1.2099609375
▁clin 2.732421875
ical 0.0080718994140625
▁settings 2.26953125
. 0.06585693359375
<0x0A> 0.309326171875
The 3.080078125
▁ES 6.61328125
MO 0.059814453125
▁meeting 2.6875
▁provides 3.74609375
▁an 0.8037109375
▁opport 5.359375
une 0.00835418701171875
▁platform 0.67919921875
▁for 0.46630859375
▁research 2.107421875
ers 0.016937255859375
▁and 1.046875
▁ph 4.76953125
arma 0.0045166015625
ce 0.07769775390625
ut 2.4318695068359375e-05
ical 0.00031447410583496094
▁companies 0.7216796875
▁to 0.1864013671875
▁show 3.212890625
case 0.005832672119140625
▁their 0.98486328125
▁adv 4.70703125
anc 0.205078125
ements 1.049041748046875e-05
▁and 1.48046875
▁eng 6.18359375
age 0.0139312744140625
▁in 0.83349609375
▁discuss 1.544921875
ions 0.0009975433349609375
▁surrounding 2.638671875
▁cutting 5.3828125
- 0.07415771484375
edge 0.001789093017578125
▁cancer 1.2841796875
▁ther 2.341796875
ap 0.059234619140625
ies 8.571147918701172e-05
. 0.457275390625
▁Anal 6.10546875
yst 0.11444091796875
s 0.0281829833984375
▁eager 5.12109375
ly 1.0517578125
▁anticip 0.460693359375
ate 0.0177154541015625
▁the 0.95654296875
▁presentation 2.5
▁on 6.390625
▁Mar 0.95263671875
im 0.0018901824951171875
ast 0.0101318359375
at 0.0009012222290039062
, 0.86474609375
▁as 1.9072265625
▁it 1.212890625
▁is 1.6435546875
▁anticip 2.763671875
ated 0.0004467964172363281
▁to 0.36474609375
▁provide 1.33203125
▁cru 5.20703125
cial 0.0002206563949584961
▁ins 0.7275390625
ights 0.000133514404296875
▁into 0.4736328125
▁its 1.673828125
▁potential 1.658203125
▁as 2.486328125
▁a 0.2325439453125
▁vi 5.41796875
able 0.00020623207092285156
▁anti 2.341796875
- 0.00714111328125
can 0.06976318359375
cer 0.00031280517578125
▁treatment 0.63427734375
. 0.53271484375
<0x0A> 0.364013671875
If 6.20703125
▁the 3.080078125
▁data 2.85546875
▁presented 1.4931640625
▁at 0.68896484375
▁the 0.3310546875
▁ES 1.0205078125
MO 0.0017251968383789062
▁meeting 0.71826171875
▁align 6.41015625
s 0.303955078125
▁with 0.2059326171875
▁previous 3.2890625
▁studies 1.0888671875
, 0.26171875
▁Mar 0.447998046875
im 0.0015621185302734375
ast 0.00469207763671875
at 0.0004458427429199219
▁could 1.5126953125
▁potentially 2.75
▁revolution 4.5234375
ize 0.01264190673828125
▁the 0.51904296875
▁field 2.916015625
▁of 0.052764892578125
▁on 0.681640625
col 0.005672454833984375
ogy 0.0005621910095214844
, 1.7353515625
▁offering 1.5
▁new 2.3515625
▁hope 0.61962890625
▁for 1.23828125
▁patients 0.681640625
▁batt 2.486328125
ling 6.651878356933594e-05
▁various 1.771484375
▁forms 1.3095703125
▁of 0.002567291259765625
▁cancer 0.0931396484375
. 0.0992431640625
▁However 3.18359375
, 0.0005593299865722656
▁it 2.736328125
▁is 0.40380859375
▁worth 4.73046875
▁not 0.1376953125
ing 0.00016307830810546875
▁that 0.007061004638671875
▁the 1.2998046875
▁drug 3.12109375
▁is 1.5302734375
▁still 0.51123046875
▁in 0.295166015625
▁the 0.85009765625
▁early 0.3720703125
▁stages 0.0758056640625
▁of 0.025177001953125
▁development 0.277099609375
, 0.6953125
▁and 0.2049560546875
▁further 1.1162109375
▁clin 2.04296875
ical 0.0007171630859375
▁tri 0.71435546875
als 5.841255187988281e-06
▁and 2.203125
▁regul 5.58203125
atory 8.952617645263672e-05
▁appro 0.5517578125
val 2.753734588623047e-05
s 1.0546875
▁will 2.380859375
▁be 0.041473388671875
▁necessary 1.3701171875
▁before 0.356201171875
▁it 0.5703125
▁can 0.578125
▁be 0.31201171875
▁made 1.615234375
▁widely 2.06640625
▁available 0.043792724609375
▁to 1.572265625
▁patients 0.5087890625
. 0.11126708984375
<0x0A> 0.42138671875
As 4.2109375
▁the 1.494140625
▁ES 2.908203125
MO 0.00479888916015625
▁meeting 0.39794921875
▁approaches 1.4794921875
, 0.04559326171875
▁anticip 5.25
ation 0.311279296875
▁is 0.480224609375
▁pal 7.19140625
p 0.0006041526794433594
able 0.0012769699096679688
▁among 1.9560546875
▁anal 1.2783203125
yst 2.6345252990722656e-05
s 0.002254486083984375
▁who 3.720703125
▁are 0.513671875
▁closely 2.935546875
▁monitoring 0.9990234375
▁develop 1.99609375
ments 2.8848648071289062e-05
▁in 1.7763671875
▁cancer 2.42578125
▁research 2.025390625
. 0.49609375
▁The 2.1015625
▁presentation 4.0078125
▁on 1.0810546875
▁Mar 0.0517578125
im 0.00048065185546875
ast 0.004901885986328125
at 0.0001405477523803711
▁holds 5.58984375
▁the 1.0107421875
▁promise 2.861328125
▁of 0.1673583984375
▁providing 1.4091796875
▁additional 4.6640625
▁evidence 3.36328125
▁and 3.576171875
▁further 5.3359375
ing 3.828125
▁our 2.552734375
▁understanding 0.018310546875
▁of 0.0185699462890625
▁this 1.4052734375
▁innov 3.783203125
ative 0.0016613006591796875
▁treatment 1.580078125
' 4.484375
s 0.00023663043975830078
▁potential 0.227783203125
▁to 2.111328125
▁combat 1.41015625
▁cancer 0.7412109375
, 2.73046875
▁insp 6.68359375
iring 0.0072479248046875
▁hope 1.3447265625
▁for 1.3271484375
▁a 2.857421875
▁future 1.7412109375
▁where 1.833984375
▁more 3.404296875
▁effective 3.458984375
▁ther 1.65234375
ap 0.00505828857421875
ies 2.4199485778808594e-05
▁may 3.982421875
▁be 0.307373046875
▁available 0.481689453125
▁to 0.6748046875
▁those 2.0
▁in 1.5595703125
▁need 0.012481689453125
. 0.057891845703125
